# 2020 Emerging Therapies for PBC, NASH ESLD and HCC Seminar Series

## San Diego, CA – September 26, 2020

### Conference Location

San Diego Marriott La Jolla  
4240 La Jolla Village Drive  
La Jolla, California 92037  
Phone: (858)-587-1414  

### Parking at the Conference

A reduced parking rate of $10 for the day has been arranged for all seminar participants. Please bring your ticket to the Seminar Registration Desk to pick up the discount voucher. Street parking is also available.

### Driving Directions

**From Interstate 5 - Northbound**: Exit La Jolla Village Drive and turn right toward East. Turn left on Regents Road and immediately turn right to Regent Park Row. Hotel driveway is on the right side.

**From Interstate 5 - Southbound**: Exit La Jolla Village Drive and turn left toward the East. Turn left on Regents Road and immediately turn right to Regent Park Row. Hotel driveway is on the right side.

### Seminar Agenda and Syllabus Information

Registration and breakfast begin at **7:30 a.m.** in the Coronado Room. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the App will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>Registration, Continental Breakfast &amp; View Exhibits</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Opening Comments and Pre-Test</td>
</tr>
<tr>
<td>8:20 am</td>
<td>End Stage Liver Disease: Treatment, Managing Complications and Transplant</td>
</tr>
<tr>
<td></td>
<td>• Staging, workup, and diagnosis of cirrhosis</td>
</tr>
<tr>
<td></td>
<td>• Medical care of the patient with end stage liver disease</td>
</tr>
<tr>
<td></td>
<td><strong>Liver Transplantation</strong></td>
</tr>
<tr>
<td></td>
<td>• Listing criteria, MELD scores, Exceptions and the transplant process</td>
</tr>
<tr>
<td></td>
<td><strong>Case Study 1</strong> – Cirrhosis and Encephalopathy</td>
</tr>
<tr>
<td>9:25 am</td>
<td>Hepatocellular Carcinoma (HCC)</td>
</tr>
<tr>
<td></td>
<td>• Screening diagnostic serum assays and imaging tests</td>
</tr>
<tr>
<td></td>
<td>• Diagnosis without histology</td>
</tr>
<tr>
<td></td>
<td>• Treatment and management options: Ablation, TACE and Surgery</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Break &amp; View Exhibits</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Hepatocellular Carcinoma: New Systemic Treatment Options</td>
</tr>
<tr>
<td></td>
<td>• Current FDA-Approved Therapies</td>
</tr>
<tr>
<td></td>
<td>• New chemotherapy regimens in development and testing</td>
</tr>
<tr>
<td></td>
<td>• Immunotherapy as the new MoA for HCC</td>
</tr>
<tr>
<td></td>
<td><strong>Case Study 2</strong> – Diagnosis and Treatment of Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis</td>
</tr>
<tr>
<td></td>
<td>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</td>
</tr>
<tr>
<td></td>
<td>• Predicting outcomes and Improving Survival in PSC patients</td>
</tr>
</tbody>
</table>
Causes and Markers of PBC
Ursodeoxycholic Acid (UDCA) and Obeticholic Acid

11:40 am  Hepatology Update I – Viral Hepatitis
- The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs

12:15 pm  Luncheon Presentation

12:55pm  Dessert and View Exhibits

1:10pm  Hepatology Update II Emerging Topics in Liver Disease
- Alcoholic Liver Disease, Liver disease and Pregnancy, Hepatorenal syndrome

1:40 pm  NAFLD, LAL-D and NASH
- Epidemiology, Demographics and Diagnosis
- Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
- Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease

2:15 pm  Break & View Exhibits

2:30 pm  NASH Treatments in Practice and in Development
- Current therapies for NASH
- Life style changes as a therapy
- Drugs in clinical development for NASH
Case Study 3 - NASH Diagnosis and Treatment

3:30 pm  Post-test and Wrap-Up

Attendance Policies

Recording and Photography
The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance
All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation
The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information
Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.
CATHERINE FRENETTE, MD
Dr. Carrie Frenette is the Medical Director of Liver Transplantation in the Department of Organ Transplantation at Scripps Green Hospital, San Diego, CA. She also serves as the Director, Hepatocellular Carcinoma Program for Scripps. She received his bachelor’s degree in Biology from Loyola University in Chicago, IL and her medical degree from Rush Medical College, also in Chicago. Dr. Frenette is widely published in many peer-reviewed journals.

Dr. Frenette is active in many professional societies including: the American Gastroenterology Association; American College of Gastroenterology; European Association for the Study of the Liver; The Transplantation Society; the International Liver Cancer Association and the American Liver Foundation.

MAZEN NOUREDDIN, MD, MHSc
Dr. Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World report. His focus is on clinical and translational research in the area of NAFLD.

Dr. Noureddin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He was one of the authors who established MRI-PDFF as a precise biomarker for measurement of liver fat in patients with NAFLD/ NASH.

LISA RICHARDS, FNP-BC, MSN
Lisa Richards is a board certified Family Nurse Practitioner with the University of California Medical Center, San Diego. She received her bachelor and master’s of science degree in nursing, magna cum laude, from the University of San Diego.

She practices in hepatology and has over 15 years of experience. She is a member of the American Association for the Study of Liver Disease and has served on many committees and is currently co-chair of the Hepatology Associate Special Interest Group. Additionally, she is chair of the local American Liver Foundation Associate Medical Advisory Committee. She is very active in the field of Hepatology and is an international and national speaker.